摘要
紫杉醇新剂型较好地解决了紫杉醇水溶性差和辅助溶剂聚氧乙烯蓖麻油(Cremophor EL)的毒性问题,临床使用均不需抗过敏预处理,并在药代、药效及毒性反应方面显示了不同的优势,具有良好的临床应用前景。本文综述近年来研发的紫杉醇新剂型及其临床应用进展。
The results of preliminary study show that these formulations can increase the solubility of paclitaxed in water or decrease adverse reactions of the Cremophor EL. These formulations can avoid anti-allergy pretreatment in clinic and improve the advantage in pharmacokinetic, pharmacodynamics or toxicity. These formulations give a good perspective in clinical development. This article reviewed the development of some new formulations and clinical application of paclitaxel in recent years.
出处
《世界临床药物》
CAS
2009年第5期297-300,共4页
World Clinical Drug
关键词
紫杉醇
进展
剂型
paclitaxel
progress
formulations
